UA88523C2 - Фармацевтический препарат рофлумиласта для местного применения - Google Patents

Фармацевтический препарат рофлумиласта для местного применения

Info

Publication number
UA88523C2
UA88523C2 UAA200712909A UAA200712909A UA88523C2 UA 88523 C2 UA88523 C2 UA 88523C2 UA A200712909 A UAA200712909 A UA A200712909A UA A200712909 A UAA200712909 A UA A200712909A UA 88523 C2 UA88523 C2 UA 88523C2
Authority
UA
Ukraine
Prior art keywords
dosage form
roflumilast
topical administration
namely
human body
Prior art date
Application number
UAA200712909A
Other languages
English (en)
Ukrainian (uk)
Inventor
Крістіна Болле
Рудольф Ліндер
Original Assignee
Алтана Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алтана Фарма Аг filed Critical Алтана Фарма Аг
Publication of UA88523C2 publication Critical patent/UA88523C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к отрасли фармацевтической технологии, в частности к фармацевтическому препарату для местного применения, предназначенному для введения в организм слаборастворимого ингибитора PDE 4 – рофлумиласта, в форме мази, содержащей парафин, пригодный для местного применения и жидкий при температуре тела.
UAA200712909A 2002-05-28 2003-05-27 Фармацевтический препарат рофлумиласта для местного применения UA88523C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10223828 2002-05-28
EP02011830 2002-05-28
DE10311613 2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation

Publications (1)

Publication Number Publication Date
UA88523C2 true UA88523C2 (ru) 2009-10-26

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200712909A UA88523C2 (ru) 2002-05-28 2003-05-27 Фармацевтический препарат рофлумиласта для местного применения
UA20041210683A UA81910C2 (ru) 2002-05-28 2003-05-27 Фармацевтический препарат для местного накожного применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA20041210683A UA81910C2 (ru) 2002-05-28 2003-05-27 Фармацевтический препарат для местного накожного применения

Country Status (32)

Country Link
US (7) US20060084684A1 (ru)
EP (3) EP2020243B1 (ru)
JP (3) JP2005529928A (ru)
KR (2) KR101307093B1 (ru)
CN (3) CN101491520B (ru)
AT (2) ATE417628T1 (ru)
AU (2) AU2003240719B2 (ru)
BR (2) BR0311337A (ru)
CA (2) CA2486910C (ru)
CY (2) CY1110312T1 (ru)
DE (2) DE60334692D1 (ru)
DK (3) DK2020243T3 (ru)
EA (2) EA010416B1 (ru)
ES (3) ES2693094T3 (ru)
HR (1) HRP20041211B1 (ru)
HU (1) HUE039709T2 (ru)
IL (3) IL164935A (ru)
IS (1) IS2639B (ru)
LT (1) LT2020243T (ru)
MA (1) MA27813A1 (ru)
ME (1) ME00565A (ru)
MX (2) MXPA04011612A (ru)
NO (2) NO334882B1 (ru)
NZ (3) NZ536920A (ru)
PL (3) PL397021A1 (ru)
PT (3) PT1511516E (ru)
RS (1) RS51104B (ru)
SI (2) SI2020243T1 (ru)
TR (1) TR201815573T4 (ru)
UA (2) UA88523C2 (ru)
WO (2) WO2003099278A1 (ru)
ZA (2) ZA200408649B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
BR0314603A (pt) 2002-09-20 2005-07-26 Alcon Inc Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
WO2005067892A1 (en) * 2004-01-10 2005-07-28 Biolipid, Inc. Lipid compositions and methods of use
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
CN101687820B (zh) 2007-08-17 2012-07-25 卫材R&D管理有限公司 喹唑啉衍生物的制造方法
CN101687819B (zh) 2007-08-17 2013-03-20 卫材R&D管理有限公司 外用剂
IN2012DN03631A (ru) 2009-10-30 2015-06-26 Nestec Sa
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
JP5998213B2 (ja) * 2011-06-28 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ レゴラフェニブを含有する眼科用局所医薬組成物
EP2836240B1 (en) * 2012-04-10 2019-03-13 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2014072937A1 (en) * 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
CN106573889B (zh) * 2014-10-24 2019-01-01 久光制药株式会社 前药
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CN115551478A (zh) 2020-01-31 2022-12-30 阿尔库缇斯生物疗法股份有限公司 具有改善递送和血浆半衰期的罗氟司特局部制剂
WO2021226370A1 (en) * 2020-05-07 2021-11-11 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CA3206106A1 (en) * 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
WO2022256412A2 (en) * 2021-06-01 2022-12-08 Eyedea Bio, Llc Extended release drug delivery system for ocular drugs and methods of use
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
IL313616A (en) 2021-12-17 2024-08-01 Aerie Pharmaceuticals Inc Ophthalmic pharmaceutical compositions and uses thereof
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US20250082618A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
WO2025059531A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Topical roflumilast for the treatment of atopic/seborrheic dermatitis
WO2025080415A1 (en) 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) * 2023-11-29 2024-01-30 沈阳药科大学 一种罗氟司特油凝胶及其制备方法
WO2025221488A1 (en) 2024-04-16 2025-10-23 Alto Neuroscience, Inc. Transdermal administration of pde4 inhibitors for reduction in adverse events
WO2025265054A2 (en) 2024-06-21 2025-12-26 Arcutis Biotherapeutics, Inc. Methods of treatment using topical roflumilast compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US5747069A (en) * 1993-08-10 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Percutaneously absorbable preparation
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
TR200100893T2 (tr) * 1998-09-29 2001-11-21 Fujisawa Pharmaceutical Co., Ltd. Piridopirazin bileşiğinin yeni tuzları ve bunların kristalleri
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
EP1161239B1 (en) 1999-03-10 2004-10-20 ALTANA Pharma AG 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AP2002002446A0 (en) * 1999-10-29 2002-03-31 Smithkline Beecham Corp Method for administering a phosphodiesterase 4 inhibitor.
AU2700301A (en) * 2000-01-31 2001-08-14 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
AU2001238288A1 (en) * 2000-02-16 2001-08-27 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.

Also Published As

Publication number Publication date
KR20110122230A (ko) 2011-11-09
JP2005529930A (ja) 2005-10-06
AU2003232828A1 (en) 2003-12-12
HK1079445A1 (zh) 2006-04-07
JP5652983B2 (ja) 2015-01-14
UA81910C2 (ru) 2008-02-25
CA2486917A1 (en) 2003-12-04
CN101491520A (zh) 2009-07-29
AU2003240719B2 (en) 2009-12-10
EA200702588A1 (ru) 2008-08-29
PL372082A1 (en) 2005-07-11
MA27813A1 (fr) 2006-04-03
DE60325354D1 (de) 2009-01-29
RS101404A (sr) 2007-02-05
CN1655782A (zh) 2005-08-17
PL372095A1 (en) 2005-07-11
NO334916B1 (no) 2014-07-14
US20190029956A1 (en) 2019-01-31
US20080280958A1 (en) 2008-11-13
MXPA04011612A (es) 2005-03-07
CN100490804C (zh) 2009-05-27
NZ536920A (en) 2007-04-27
HUE039709T2 (hu) 2019-01-28
IL164935A0 (en) 2005-12-18
ATE417628T1 (de) 2009-01-15
EA200401517A1 (ru) 2005-06-30
ES2354971T3 (es) 2011-03-21
PL212134B1 (pl) 2012-08-31
ZA200409584B (en) 2006-05-31
LT2020243T (lt) 2018-11-12
IL164935A (en) 2010-12-30
PT1511516E (pt) 2009-02-20
CN101491520B (zh) 2011-03-16
HRP20041211B1 (hr) 2013-06-30
EP1511481A1 (en) 2005-03-09
HRP20041211A2 (hr) 2006-04-30
NO20045656L (no) 2004-12-27
ATE485821T1 (de) 2010-11-15
IS7612A (is) 2004-12-23
US20060084685A1 (en) 2006-04-20
WO2003099334A1 (en) 2003-12-04
CN1655823B (zh) 2010-05-26
NZ553731A (en) 2007-07-27
AU2003232828B2 (en) 2010-06-24
PT1511481E (pt) 2011-01-14
BR0311339A (pt) 2005-03-22
NZ537308A (en) 2009-09-25
PL211870B1 (pl) 2012-07-31
CN1655823A (zh) 2005-08-17
CY1110312T1 (el) 2015-01-14
TR201815573T4 (tr) 2018-11-21
ES2693094T3 (es) 2018-12-07
EP1511516B1 (en) 2008-12-17
CA2486910C (en) 2011-11-29
BR0311337A (pt) 2005-03-15
US20210116207A1 (en) 2021-04-22
MXPA04011528A (es) 2005-02-14
CA2486917C (en) 2011-11-22
AU2003240719A1 (en) 2003-12-12
IS2639B (is) 2010-06-15
JP2012229245A (ja) 2012-11-22
EP2020243A1 (en) 2009-02-04
EP1511516A1 (en) 2005-03-09
NO20045506L (no) 2004-12-16
DK2020243T3 (en) 2018-11-19
KR20050014844A (ko) 2005-02-07
CA2486910A1 (en) 2003-12-04
HK1079437A1 (en) 2006-04-07
IL165065A0 (en) 2005-12-18
SI1511516T1 (sl) 2009-06-30
JP5683538B2 (ja) 2015-03-11
CY1121133T1 (el) 2019-12-11
SI2020243T1 (sl) 2018-11-30
ZA200408649B (en) 2007-12-27
DK1511481T3 (da) 2011-01-24
KR101307093B1 (ko) 2013-09-11
DE60334692D1 (de) 2010-12-09
US20140303215A1 (en) 2014-10-09
WO2003099278A1 (en) 2003-12-04
EP2020243B1 (en) 2018-08-15
PL397021A1 (pl) 2012-03-26
ES2319517T3 (es) 2009-05-08
PT2020243T (pt) 2018-11-09
EA010416B1 (ru) 2008-08-29
IL165065A (en) 2010-11-30
EA020569B1 (ru) 2014-12-30
JP2005529928A (ja) 2005-10-06
NO334882B1 (no) 2014-06-30
DK1511516T3 (da) 2009-04-06
IL209657A0 (en) 2011-02-28
ME00565A (en) 2011-12-20
RS51104B (sr) 2010-10-31
EP1511481B1 (en) 2010-10-27
US20060084684A1 (en) 2006-04-20
US20110313005A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
SE9804314D0 (sv) New pharmaceutical formulation
MY129422A (en) Medicinal compounds
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
WO2004037768A3 (en) Phenethanolamine derivatives
GB0112348D0 (en) Compounds
TW200510375A (en) New compounds
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
IL165065A (en) Pharmaceutical compositions containing roflumilast for treatment of eye disease
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2004026306A3 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
SE0100569D0 (sv) New compounds
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
SE0102440D0 (sv) New compound
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
ATE360428T1 (de) Analgetisches arzneimittel
MXPA04004443A (es) Derivados de pirazol.
SE0201837D0 (sv) Chemical compounds